More stories

  • in

    Women are fueling the box office in China and Hollywood should take note

    Women are fueling China’s box office, according to a Morning Consult survey. This marks a cultural shift in the country and a new entry point for Hollywood studios.
    While women account for less than half the region’s population, they represent 52% of monthly moviegoers.
    As movie theaters reopened in the wake of the Covid-19 pandemic, Hollywood has been quick to offer up superhero and action films to Chinese audiences to middling success.

    Fans watch a movie at a cinema in Shanghai.
    Future Publishing | Future Publishing | Getty Images

    Women are fueling China’s box office despite making up a smaller share of the population — and Hollywood should take note.
    While women account for less than half the Chinese population, they represent 52% of monthly moviegoers, according to Morning Consult, which surveyed 681 monthly moviegoers between July 21 and July 25.

    The higher-than-expected box office spending by Chinese women not only shows a cultural shift, but also a new entry point for American studios. Hollywood has struggled to regain its foothold in the country after Covid-19 pandemic shutdowns, as China developed its domestic film industry and limited the number of foreign films allowed in theaters. Tapping into this new trend of female moviegoers in China could be a new strategy for Hollywood.
    Morning Consult determined that female audiences in China are interested in science fiction and action films, on par with their male counterparts, but over index in interest in romantic comedies and musicals.
    “Which I think speaks to why ‘Barbie’ recently was able to take off in that country, like it did in many other places,” said Kevin Tran, senior media and entertainment analyst at Morning Consult.
    While Warner Bros.’ “Barbie” has collected only about $35 million so far in China, Tran suggests studios could look to capitalize on a demographic that is being underserved in the marketplace.
    “Purchasing power of women in China has been increasing for several years,” Tran explained. “Fewer women are getting married. So there’s, I think there’s just more independence, and I think that with China still being a country that has prioritized traditional gender roles … there’s more time to be had for leisure and things besides domestic or house care type of responsibilities. … So they’re able to do other things, like go to the movies, or just spend money on themselves in a way that they might not have been able to previously.”

    Morning Consult noted that its survey indicated that 32% of Chinese women reported going to the movies three or more times in the month of July, compared with 27% of men.
    “Given the difficulty nonlocal studios face in nailing down specific cultural norms and pop culture references in China, it could make sense for U.S. studios to more heavily invest in Chinese productions of musicals and romantic comedies as a longer-term strategy,” Tran wrote in his report. “These investments would be one way to ensure that studios’ slates are balanced with genres beyond the typical big-budget action blockbusters they’ve traditionally relied upon for global box office success.”
    Tran said that Hollywood shouldn’t completely rewrite it’s playbook to cater to one country’s cinematic inclinations. After all, American audiences have rebuked studios for altering or even cutting scenes from films to cater to Chinese censorship rules.
    To be distributed and screened in China, films must be approved by regulators and could be censored if they contain content that officials deem violates its core socialist values or detracts from its nationalistic image. 
    Several major blockbusters, including Marvel’s “Black Widow,” “Shang-Chi and the Legend of the Ten Rings,” “Thor: Love and Thunder,” “Doctor Strange in the Multiverse of Madness” and Sony’s “Spider-Man: No Way Home,” were barred from Chinese theaters.

    Before the pandemic, Chinese audiences were consistently responsible for between 15% and 20% of global hauls for big blockbusters, especially in the Marvel Cinematic Universe. For the most recently released Marvel film, “Guardians of the Galaxy Vol. 3,” ticket sales from China accounted for just 10% of the film’s total haul.
    As movie theaters reopened in the wake of the pandemic, Hollywood has been quick to offer up superhero and action films to Chinese audiences to middling success. While Disney’s “Avatar: The Way of Water” snared more than $200 million during its theatrical run in the country, few others have come close to that figure, or even crossed the $100 million mark.
    China resumed importing Hollywood films at pre-pandemic levels this year, but ticket sales during the first half of 2023 are down nearly 70% from the same period in 2019, according to film industry advisory group Artisan Gateway. More

  • in

    Taylor Swift’s Eras Tour concert movie could make $100 million in its first weekend

    Days after Taylor Swift announced her Eras Tour concert film would come to domestic movie theaters in October, tickets have been selling fast.
    While it’s early, some box office analysts see a potential $100 million opening for the film.
    The movie is set to open Oct. 13 in several North American theater chains.

    Taylor Swift performs onstage during her The Eras Tour at Lumen Field in Seattle, July 22, 2023.
    Mat Hayward/tas23 | Getty Images Entertainment | Getty Images

    Taylor Swift is already a superstar. Now, she’s about to put up superhero-style numbers at movie theaters.
    Days after the pop icon announced her Eras Tour concert film would come to domestic movie theaters in October, tickets have been selling fast. The flurry of presales have led theaters big and small to add additional showtimes to meet demand.

    Box office analysts aren’t being conservative about their opening weekend expectations. Many foresee Swift’s big screen experience to top $100 million during its debut.
    “It is still very early days for such a highly unique release,” said Shawn Robbins, chief analyst at BoxOffice.com. “That said, nine digits looks very attainable for opening weekend if capacity continues to grow with additional theaters and showtimes, and especially if promotion ramps up more in the next few weeks to attract the non-Swifties as part of a true theatrical event.”
    At its current pace, Robbins said he wouldn’t be surprised to see the film deliver the best opening of any film released in the fourth quarter, especially as many theaters have teased that they will have unique in-cinema experiences just for the occasion. The Warehouse Cinemas chain, for example, plans to roll out a cotton candy drink with a glitter rim — available as a cocktail and a nonalcoholic mocktail — and popcorn with edible glitter for fans who dress up for the movie.

    $100 million opening weekends in 2023

    “Barbie” (Warner Bros.) – $162 million
    “The Super Mario Bros. Movie” (Universal) – $146.3 million
    “Spider-Man: Across the Spider-Verse” (Sony) – $120.6 million
    “Guardians of the Galaxy Vol. 2” (Disney) – $118.4 million
    “Ant-Man and the Wasp: Quantumania” (Disney) – $106.1 million

    Source: Comscore

    The surprise movie announcement comes at a time when several big-budget features are fleeing the release calendar. Warner Bros. and Legendary Entertainment’s “Dune: Part Two,” plus Sony’s “Kraven the Hunter” and the “Ghostbusters: Afterlife” sequel have all departed for 2024 amid dual Hollywood labor strikes.

    Warner Bros.’ DC Comics sequel “Aquaman and the Lost Kingdom” and “Charlie and the Chocolate Factory” prequel “Wonka,” alongside Disney and Marvel Studios’ “The Marvels,” are still on the slate for 2023.
    The film is bypassing the traditional studio system model and will be distributed directly by AMC Entertainment. The largest movie chain in the world is expected to pick up a 5% to 6% distribution fee.
    Additionally, tickets for the film are priced higher than typical general admission seats. Base prices start at $19.89 for adults and $13.13 for kids. The numbers reflect Swift’s birth year and her lucky number 13. Tickets for premium format screens such as IMAX and Dolby come at a higher cost.
    The film is set to run Thursday through Sunday until Nov. 5, although some have speculated that high box office numbers could prolong its stay in theaters.

    “The overwhelming response to news of the movie’s release and subsequent ticket buying frenzy has taken the box office projections to the next level and could create a new model for how to boost movie theater revenues with special events and nontraditional filmed content,” said Paul Dergarabedian, senior media analyst at Comscore.
    Swift’s concert film seems destined to overtake the current record holder for a theatrical concert film. Miley Cyrus’ “Best of Both Worlds” concert film tallied $31.1 million during its opening weekend back in 2008. It ultimately snared $70 million globally, according to Comscore data.
    “No matter where things land, Eras is already a thunderous success and a welcome addition for theatrical exhibition who have been at the mercy of Hollywood’s strike-induced delays of other tentpole films previously slated for the coming months,” Robbins said. “It’s a shining example of Taylor’s remarkable following and her business acumen in a year which she’s already dominated the pop culture landscape.”
    Disclosure: Comcast is the parent company of NBCUniversal and CNBC. NBCUniversal is the distributor of “The Super Mario Bros. Movie.” More

  • in

    Stocks making the biggest moves midday: Halliburton, Warner Bros. Discovery, Oracle and more

    In this photo illustration, the Warner Bros. Discovery logo is displayed on a smartphone screen.
    Rafael Henrique | SOPA Images | Lightrocket | Getty Images

    Occidental Petroleum, Halliburton, EOG Resources — Shares of oil and gas companies were higher Tuesday after Saudi Arabia earlier extended its one million barrel per day voluntary crude oil production cut until the end of the year. Occidental Petroleum gained about 2.5%. Halliburton added 2.7% and EOG Resources rose 1.8%. The cut, which led oil prices higher during the day, adds to other voluntary crude output declines that some members of OPEC have put in place until the end of 2024.
    Oracle — The software stock climbed 2.5% on the back of an upgrade to overweight from equal weight by Barclays. The firm said the company’s cloud business should be helped by artificial intelligence.

    Airbnb — Shares rose 7.2% on the back of S&P Dow Jones Indices’ Friday announcement that the stock would join the S&P 500 starting Sept. 18. The S&P 500 is widely tracked by large index funds, which could create buying pressure on Airbnb’s stock in the weeks ahead.
    Blackstone — Shares of the asset management company gained 3.6% on news that the stock will join the S&P 500 before the open on Sept. 18, as part of a quarterly rebalance for S&P Indices.
    Warner Bros. Discovery — The media stock added 0.7% during Tuesday’s trading session after Warner Bros. said it still expects to hit its net leverage target, despite taking a hit of $300 million to $500 million in its adjusted earnings before interest, taxes, depreciation and amortization. That puts its adjusted earnings in the full-year range of $10.5 billion to $11 billion. Warner Bros. said its adjusted full-year expectation assumes the financial effect of the writers and actors strikes will persist through the end of the year.
    NextGen Healthcare — Shares of the health-care company popped 6.3% Tuesday following a Bloomberg report Monday that the company was in late-stage talks with potential acquirer Thoma Bravo.
    Brady — The manufacturing stock gained 11.4% after the company reported quarterly results. Brady posted an adjusted $1.04 in profit per share for its fiscal fourth quarter, while analysts polled by FactSet forecast 93 cents.

    PulteGroup, Lennar — Homebuilder stocks took a breather Tuesday. The industry has been on fire in 2023, propelled by a shortage of homes for sale. PulteGroup and Lennar fell during the day’s trading session, losing 5.7% and 4.9%, respectively.
    — CNBC’s Brian Evans, Alex Harring and Hakyung Kim contributed reporting. More

  • in

    The $100trn battle for the world’s wealthiest people

    The uber-rich hire all kinds of people to make their lives easier. Landscapers maintain gardens, housekeepers tidy homes, nannies raise children. Yet perhaps no role is as important as that of the wealth manager, who is hired to protect capital.These advisers are scattered across the globe in cities such as Geneva and New York, and are employed as fiduciaries, meaning they are required to act in the interest of their clients. As such, they become privy to the intimate lives of the rich and famous, who must expose their secrets so that advice may be offered on, say, the inheritance of a child born of an extramarital affair. Advisers also help families allocate investments, stash cash in boltholes, minimise tax bills, plan for retirement, arrange to pass down their vast wealth and follow unusual wishes. A Singapore-based manager recalls being told to invest a “double-digit” percentage of a family’s wealth in “bloodstock horses”—steeds bred especially for racing—a term he hurriedly looked up after the meeting.For decades, wealth management was a niche service, looked down upon by the rest of finance. Now it is the most attractive business in the industry. Capital and liquidity requirements set after the global financial crisis of 2007-09 have made running balance-sheet-heavy businesses, such as lending or trading, difficult and expensive. By comparison, doling out wealth advice requires almost no capital. Margins for firms that achieve scale are typically around 25%. Clients stick around, meaning that revenues are predictable. Competition has crushed profits in other formerly lucrative asset-management businesses, such as mutual funds. And whereas the pools of assets managed by BlackRock and Vanguard, the index- and exchange-traded-fund giants, are huge, they collect a fraction of a penny on every dollar invested. A standard fee for a wealth manager is 1% of a client’s assets, annually.Wealth management is all the more appealing because of how quickly it is expanding. Global economic growth has been decent enough over the past two decades, at more than 3% a year. Yet it has been left in the dust by growth in wealth. Between 2000 and 2020 it rose from $160trn, or four times global output, to $510trn, or six times output. Although much of this is tied up in property and other assets, the pool of liquid assets is still vast, making up a quarter of the total. Bain, a consultancy, estimates that it will almost double, from just over $130trn to almost $230trn by 2030—meaning that a $100trn prize is up for grabs. They anticipate the boom will help lift global wealth-management revenues from $255bn to $510bn.image: The EconomistIt will be fuelled by geography, demography and technology. The biggest managers are attempting to cover ever more of the globe as dynastic wealth is created in Asian and Latin American markets. Baby-boomers are the last generation that can rely on defined-benefit pensions for their retirement; more people will have to take decisions about how their own wealth will support them. Meanwhile, software is streamlining the bureaucracy that once waylaid wealth managers, allowing them to serve more clients at lower cost, and helping firms automate the acquisition of new ones. These gains will allow big banks to serve the merely rich as well as the uber-wealthy. Firms are already climbing down the rungs of the wealth ladder, from ultra-high-net-worth and high-net-worth, who have millions of dollars to invest, into the lives of those with just $100,000 or so.Markus Habbel of Bain sees a comparison to the booming luxury-goods industry. Handbags were once prized for their exclusivity as much as their beauty, but have become ubiquitous on social media, with influencers touting Bottega Veneta pouches and Hermès bags. “Think about Louis Vuitton or Gucci. They have basically the same clients as [wealth managers] target and they increased from 40m [customers] 40 years ago to 400m now,” he notes. Upper-crust buyers have not been put off.Which firms will grab the $100trn prize? For the moment, wealth management is fragmented. Local banks, such as btg in Brazil, have large shares of domestic markets. Regional champions dominate in hubs, including Bank of Singapore and dbs in Asia. In America the masses are served by specialist firms such as Edward Jones, a retail-wealth-mananagement outfit in which advisers are paid based on commissions for selling funds. Only a handful of institutions compete on a truly global scale. These include Goldman Sachs and JPMorgan Chase. But the two biggest are Morgan Stanley and a new-look ubs, which has just absorbed Credit Suisse, its old domestic rival. After acquiring a handful of smaller wealth-management firms over the past decade, Morgan Stanley now oversees around $6trn in wealth assets. After its merger, ubs now oversees $5.5trn.To the victorThis patchwork is unlikely to last. “The industry is heading in a winner-takes-all direction,” predicts Mr Habbel, as it becomes “very much about scale, about technology and about global reach”. Jennifer Piepszak, an executive at JPMorgan, has reported that her firm’s takeover of First Republic, a bank for the well-heeled that failed in May, represents a “meaningful acceleration” of its wealth-management ambitions. Citigroup has poached Andy Sieg, head of wealth management at Bank of America, in an effort to revamp its offering. In 2021 Vanguard purchased “Just Invest”, a wealth-technology company.ubs and Morgan Stanley have grander ambitions. The firms’ strategies reflect their contrasting backgrounds and may, ultimately, end up in a clash. Morgan Stanley competes around the world but is dominant in America, and is focusing on wealth services for the masses, as shown by its purchase of e*trade, a brokerage platform, in 2020. James Gorman, the bank’s boss, has said that if the firm keeps growing new assets by around 5% a year, its current growth rate, it would oversee $20trn in a decade or so.This would be built on Morgan Stanley’s existing scale. In 2009 the bank agreed to acquire Smith Barney, Citi’s wealth-management arm, for $13.5bn, which helped boost margins to the low teens from 2% or so in the years before the financial crisis. Today they are around 27%, reflecting the use of tech to move into advising the merely rich. Andy Saperstein, head of the wealth-management division, points to the acquisition of Solium, a small stock-plan-administration firm, which Morgan Stanley purchased for just $900m in 2019, as crucial for building a strong client-referral machine. “No one was looking at the stock-plan-administration companies because they didn’t make any money,” he says. But these firms “had access to a huge customer base and [clients] were constantly checking to see when the equity was going to vest, what it was worth and when they would have access to it.”ubs is employing a more old-school approach, albeit with a global twist. Having taken over its domestic rival, the Swiss bank has a once-in-a-generation chance to cement a lead in places where Credit Suisse flourished, such as Brazil and South-East Asia. Deft execution of the merger would make the firm a front-runner in almost every corner of the globe. Thus, for now at least, the new-look ubs will focus more on geographic breadth than the merely rich.In differing ways, both Morgan Stanley and ubs are seeking even greater scale. When clients hire a wealth manager they tend to want one of two things. Sometimes it is help with a decision “when the cost of making a bad choice is high”, says Mr Saperstein, such as working out how to save for retirement or a child’s education. Other times it is something exclusively available, such as access to investments unobtainable through a regular brokerage account.Being able to offer clients access to private funds or assets will probably become increasingly important for wealth managers. Greater scale means greater bargaining power when negotiating with private-markets firms to secure exclusive deals, such as private funds for customers or lower fees. Younger generations, which will soon be inheriting wealth, are expected to demand more environmentally and socially conscious options, including those that do not just screen out oil companies, but focus on investing in, say, clean energy. A decade ago a client would tend to follow their wealth adviser if he or she moved to a new firm. Exclusive funds make such a switch more difficult.The winner-takes-all trend may be accelerated by artificial intelligence (ai), on which bigger firms with bigger technology budgets already have a head start. There are three kinds of tools that ai could be used to create. The first take a firm’s proprietary information, such as asset-allocation recommendations or research reports, and spit out information that advisers can use to help their clients. Attempts to build such “enterprise” tools are common, since they are the easiest to produce and pose few regulatory difficulties.WealthbotsThe second type of tool would be trained on client information rather than companies’ proprietary data, perhaps even listening in on conversations between advisers and clients. Such a tool could then summarise information and create automatic actions for advisers, reminding them to send details to clients or follow up about certain issues. The third kind of tool is the most aspirational. It is an execution tool, which would allow advisers to speak aloud requests, such as purchasing units in a fund or carrying out a foreign-exchange transaction, and have a firm’s systems automatically execute that transaction on their behalf, saving time.It will take money to make money, then. The biggest wealth managers already have more substantial margins, access to products their clients want and a head start on the technology that might put them even further ahead. “We are a growth company now,” claims Mr Saperstein of Morgan Stanley, a sentence that has been rarely uttered about a bank in the past 15 years. “We are just getting started.”Yet the two giants atop the industry are both going through periods of transition. ubs has barely begun the open-heart surgery that is required when merging two large banks. Meanwhile, Mr Gorman, architect of Morgan Stanley’s wealth strategy, will retire some time in the next nine months. The succession race between Mr Saperstein, Ted Pick and Dan Simkowitz, two other executives, is already under way. Either firm could falter. Although the two are chasing different strategies, it is surely only a matter of time before they clash. ubs is on an American hiring spree; Morgan Stanley is eyeing expansion in some global markets, including Japan.And despite the advantages offered by scale, smaller wealth-management firms will be difficult to dislodge entirely. Lots of different outfits have a foothold in the industry, from customer-directed brokerage platforms like Charles Schwab, which also offer their richest customers independent advice from a fiduciary, to asset-management firms, such as Fidelity and Vanguard, which have millions of customers invested in their funds, who might seek out wealth-management advice. When Willie Sutton, a dapper thief also known as Slick Willie who died in 1980, was asked why he decided to rob banks, he replied that it was simply “because that is where the money is”. This is also a useful aphorism to explain strategy on Wall Street, as firms race to take advantage of the $100trn opportunity in wealth management. Once the business was a sleepy, unsophisticated corner of finance. Now it is the industry’s future. ■ More

  • in

    Illumina names new CEO months after Icahn proxy fight over Grail deal

    Illumina’s board named Jacob Thaysen the new CEO of the DNA sequencing company.
    Thaysen, a 48-year-old longtime executive at medical devices firm Agilent, will step in as CEO on Sept. 25.
    His nomination comes months after a bitter proxy fight with activist investor Carl Icahn, which ended with Illumina’s former CEO Francis deSouza stepping down despite securing enough votes to stay

    A building on the campus at the world headquarters of Illumina is shown in San Diego, California, Sept. 1, 2021.
    Mike Blake | Reuters

    Illumina’s board on Tuesday named Jacob Thaysen as the DNA sequencing company’s new CEO as it tries to rebound from a grinding dispute over its acquisition of cancer test developer Grail.
    Thaysen, a 48-year-old longtime executive at medical devices firm Agilent, will step in as CEO on Sept. 25. His nomination comes months after a bitter proxy fight with activist investor Carl Icahn ended with Illumina’s former CEO, Francis deSouza, resigning despite securing enough votes to stay. 

    Illumina closed its $7.1 billion acquisition of Grail in 2021 without first securing approval from antitrust regulators in the U.S. and European Union — a decision that prompted Icahn to seek board seats and push the companies to unwind the deal. 
    Shares of Illumina fell more than 4% on Tuesday after the announcement. 
    New leadership could help Illumina regain its footing after a rocky past two years. The company’s market value has fallen to roughly $25 billion from around $75 billion in August 2021, the month it closed its acquisition of Grail. 

    Jacob Thaysen
    Source: Illumina

    Thaysen will step in as Illumina fights two orders seeking to block the Grail acquisition: One from the European Commission, the EU’s executive body, and another from the U.S. Federal Trade Commission. 
    Illumina has appealed both orders and expects final decisions in late 2023 or early 2024. 

    Thaysen will join Illumina after a nearly 10-year tenure at Agilent. He led the analytical instruments division of Agilent since 2018, and served as president of the company’s diagnostics and genomics department from 2014 to 2018. 
    He nearly doubled that division’s operating profit during those four years, according to a press release from Illumina. 

    CNBC Health & Science

    Read CNBC’s latest health coverage:

    “Jacob’s unique combination of deep technological and commercial experience will be a great addition to Illumina,” Stephen MacMillan, the chair of Illumina’s board, said in the release. “He brings a fresh perspective, a demonstrated track record driving profitable growth, and a strong commitment to create value for all of Illumina’s stakeholders.”
    Thaysen will take over for Charles Dadswell, who has been serving as Illumina’s interim CEO since June. Dadswell will resume his role as senior vice president and general counsel at Illumina. More

  • in

    The FTC cleared Amgen’s $27.8 billion Horizon buyout — here’s what it means for other massive pharma deals

    The Federal Trade Commission allowed Amgen to move forward with its $27.8 billion acquisition of Horizon Therapeutics under a settlement agreement.
    Some Wall Street analysts say the FTC’s decision suggests that reviews of other pending pharmaceutical deals could potentially pan out favorably for the companies involved.
    However, other analysts and M&A experts say the settlement agreement doesn’t mean that the FTC will stop baring its teeth at other large buyouts in the industry.

    Robert Galbraith | Reuters

    The Federal Trade Commission last week allowed Amgen to move forward with its $27.8 billion acquisition of Horizon Therapeutics under a settlement agreement –  a move that could have ramifications for a string of other pharmaceutical industry buyouts.
    Some Wall Street analysts said the FTC’s decision to settle allows the sector to breathe a sigh of relief, as it suggests that other large pending deals could proceed relatively unscathed after reviews. That includes the agency’s examination of Pfizer’s proposed $43 billion purchase of cancer drug developer Seagen. 

    “The settlement materially mitigates regulatory headwinds” for the Pfizer-Seagen deal, William Blair analyst Matt Phipps said in a research note Friday. He added that the firm expects the acquisition to close at the end of the year or early 2024. 
    More broadly, the settlement is “a positive for the M&A space in the sector,” Truist analyst Robyn Karnauskas said in a research note Friday.
    But some analysts and mergers and acquisitions experts said the settlement agreement may not stop the FTC from baring its teeth at other large buyouts in the industry. Some also speculated that the restrictions imposed on Amgen as part of the settlement could have implications for other deals. 
    “I think that in a positive way, this hopefully helps other companies as they get evaluated. But I also think we’re just hearing that there’s more of an appetite to be active by the FTC,”  said Nathan Ray, a partner at digital consulting firm West Monroe who oversees health-care M&A.
    The Biden administration has moved to block a range of acquisitions across industries after decades of a light-touch approach by the government. The FTC’s lawsuit against Amgen in May was the agency’s first legal challenge to a pharmaceutical buyout in 14 years. 

    The suit also came amid a rebound in M&A activity in the industry: Pharmaceutical companies spent more than $80 billion on M&A in the first half of this year, according to data from Evaluate Pharma, putting 2023 on track to be the liveliest year for deals since 2019.
    The settlement agreement prohibits Amgen from bundling any of its products with two of Horizon’s blockbuster drugs, among other restrictions. That practice involves offering rebates or discounts on its existing products to pressure insurers and pharmacy benefit managers into favoring the Horizon products.
    BMO Capital Markets analyst Evan Seigerman said those conditions on the deal are likely a “non-factor” for Amgen, which has stated that it does not intend to bundle products. 
    Still, some analysts said the restrictions suggest the FTC could apply similar rules to other buyouts in the future.

    CNBC Health & Science

    Read CNBC’s latest health coverage:

    “We also believe this could be a theme in future M&A wherein such restrictions … will apply to all future transactions,” Truist’s Karnauskas said in a note.
    It’s unclear whether future limits imposed on other companies could have a more meaningful effect on their businesses. But analysts from Wells Fargo, in a research note Friday, said the restrictions imposed on Amgen “could pose a challenge for future deals.” 
    West Monroe’s Ray added that the settlement agreement could “open up other pharma deals for some type of review” by the FTC.
    That’s because the agency appears to be comfortable finding “fairly narrow reasons for why they may have issues” with deals, even ones that don’t appear to be creating anti-competitive situations, he said. Ray contends that the Amgen-Horizon deal doesn’t reduce competition since the two companies have vastly different drug portfolios that don’t compete – a view shared by many analysts. 
    Even so, the settlement agreement could make the pharmaceutical industry “think more” before pursuing M&A, according to the Wells Fargo analysts. 
    “We are of the view that FTC is scrutinizing bigger deals more,” the analysts wrote. They added that they believe pharmaceutical companies “would want to stay under the radar with sub $10-15B deals.”
    In a statement Friday, FTC Chair Lina Khan signaled that the agency isn’t going to let up on its antitrust scrutiny in the pharmaceutical industry. 
    The FTC will “continue to challenge unlawful practices that raise drug prices, inhibit access, stifle innovation, or otherwise hurt patients,” Khan said.
    Correction: Nathan Ray is a partner at digital consulting firm West Monroe who oversees health-care M&A. An earlier version mistakenly described the firm. More

  • in

    Can you use expired Covid tests? What to know as cases rise, new variants emerge

    Americans are digging out their unused at-home Covid-19 tests as the U.S. sees a new surge in cases.
    Some expired Covid tests are still safe to use if the Food and Drug Administration says it has an extended expiration date.
    Otherwise, using expired tests without extensions could be unreliable.

    In this photo illustration, Abbott’s at-home covid-19 rapid test kits are seen on display in Orlando.
    Paul Hennessy | LightRocket | Getty Images

    As Covid cases surge again in the U.S., Americans are digging out unused at-home tests that they stashed earlier on in the pandemic. 
    Many of those tests may have passed their expiration dates, but don’t throw them away just yet. 

    The Food and Drug Administration has extended the expiration dates of many popular at-home test products, which means some of your old kits may still be safe to use. You can check by visiting a page on the FDA’s website that lists expiration information for each test brand.
    “That’s the first thing I would do before using an expired test or throwing it away,” Andrew Pekosz, a professor at the Johns Hopkins Bloomberg School of Public Health, told CNBC.
    If the date has not changed, the FDA advises against using expired tests. Doing so increases the chance of an inaccurate test result, which could put your or another person’s health at risk. 
    A false result carries more risk again as Covid gains a greater foothold nationwide, primarily driven by newer variants of the virus like the now-dominant EG.5 strain, or “Eris.” Covid hospitalizations jumped nearly 19% last week, marking the sixth straight week of increasing admissions, according to the Centers for Disease Control and Prevention. 
    Public health experts say testing remains a critical tool for protection as Covid metrics climb. But lab PCR tests – the traditional way of detecting Covid – have become more expensive and less accessible for some Americans since the U.S. government ended the public health emergency in May. 

    The end of that declaration also changed how public and private insurers cover at-home tests, potentially leaving some people unable to get those tests for free through their plans. However, certain local health clinics and community sites still offer at-home tests to the public at no cost. 
    Before buying new at-home tests, it wouldn’t hurt to check if any expired ones sitting in your medicine cabinet are still safe to use. Here’s a walkthrough for how to do that, and everything else you need to know about these tests. 

    How to carefully check for extended expirations

    The FDA website lists Covid test brands alphabetically in a table. Or, you can use a search box to find your test directly. 
    The agency indicates whether each brand has an extended expiration date. It usually provides a link to a PDF with new expirations for specific test lots.

    Arrows pointing outwards

    Find your test’s lot number –  which is typically printed next to the expiration date on the packaging – and cross-reference it with the information on the PDF. 
    For example, a “BinaxNOW COVID-19 Ag Self Test” from lot number 181922 has a new expiration date of Oct. 11. That’s more than a year after its printed date of Sept. 11, 2022, extending the product’s total shelf life to 22 months.

    Arrows pointing outwards

    The FDA extends expiration dates when a manufacturer provides data showing that its test’s shelf life is longer than what was known when the agency first approved the product.
    “Expiration dates that were initially marked on these tests were sometimes very short because they were based on the available data at the time,” Pavitra Roychoudhury, a professor of laboratory medicine at the University of Washington School of Medicine, told CNBC. “But time has passed and more data has been gathered, so we can assess the stability and sensitivity of these tests over longer periods of time now.” 

    How at-home tests fare against new variants

    The majority of at-home tests entered the market long before Eris and other new variants emerged in the U.S. But the FDA and experts say existing at-home tests detect Covid infections caused by those new strains, most of which are descendants of omicron. 
    “With EG.5, it’s very clear that at-home tests as well as many of the other tests that are done at medical institutions, hospitals and other places all recognize that and other currently circulating variants right now,” said Johns Hopkins’ Pekosz. 

    CNBC Health & Science

    Read CNBC’s latest health coverage:

    The FDA last week also said “existing tests used to detect and medications used to treat COVID-19 continue to be effective” with another omicron subvariant called BA.2.86, which has been detected in very small numbers across the U.S.
    The CDC is tracking that variant because it has a high number of mutations that distinguish it from any other known strain of the virus. So far, there is no evidence that BA.2.86 causes more serious infections than other variants.
    But recent studies from researchers in China and Sweden suggest that BA.2.86 could be less contagious and less immune-evasive than feared. 
    “Overall, it doesn’t appear to be nearly as extreme a situation as the original emergence of Omicron,” wrote Benjamin Murrell, principal researcher of the Sweden study, in a post on X, formerly known as Twitter.  More

  • in

    Fed Governor Waller agrees the central bank can ‘proceed carefully’ on interest rates

    Fed Governor Christopher Waller told CNBC on Tuesday that “a hell of a good week of data” will buy the central bank some time on policy decisions.
    While he was encouraged by the recent reports on where prices are trending, he said they also indicate that the Fed can afford to hold rates higher until it is sure inflation is on the run.

    Federal Reserve Governor Christopher Waller said Tuesday that the recent round of strong economic data will buy the central bank some time as it decides whether additional interest rate hikes are needed to control inflation.
    “That was a hell of a good week of data we got last week, and the key thing out if it is it’s going to allow us to proceed carefully,” Waller told CNBC’s Steve Liesman during a “Squawk Box” interview. “We can just sit there, wait for the data, see if things continue.”

    Highlighting those data points was Friday’s nonfarm payrolls report, which showed better-than-expected growth of 187,000 jobs in August while average hourly earnings rose just 0.2% for the month, lower than forecast.
    Earlier in the week, other reports showed that the Fed’s preferred inflation gauge rose just 0.2% in July, and that job openings, a key measure of labor market tightness, fell to their lowest level since March 2021.
    “The biggest thing is just inflation,” Waller said. “We got two good reports in a row.” The key now is to “see whether this low inflation is a trend or if it was just an outlier or a fluke.”
    Waller is generally considered one of the more hawkish members of the rate-setting Federal Open Market Committee, meaning he has favored tighter monetary policy and higher interest rates as the central bank battles inflation that in the summer of 2022 was running at its highest rate in more than 40 years.
    While he was encouraged by the recent reports on where prices are trending, he said they also indicate that the Fed can afford to hold rates higher until it is sure inflation is on the run.

    “That depends on the data,” Waller said when asked whether the rate increases can stop. “We have to wait and see if this inflation trend is continuing. We’ve been burned twice before. In 2021, we saw it coming down and then it shot up. The end of 2022, we saw it coming down, then it all got revised away.”
    “So, I want to be very careful about saying we’ve kind of done the job on inflation until we see a couple of months continuing along this trajectory before I say we’re done doing anything,” he added.
    Markets are assigning a near certainty to the chances that the Fed skips a rate rise at its Sept. 19-20 meeting. However, there’s a 43.5% probability of an increase at the Oct.31-Nov. 1 session, according to CME Group tracking of futures pricing, indicating some uncertainty. Goldman Sachs this week said it expects the Fed is done.
    “I don’t think one more hike would necessarily throw the economy into recession if we did feel that we needed to do one,” Waller said. “It’s not obvious that we’re in real danger of doing a lot of damage to the job market, even if we raise rates one more time.”
    Waller’s remarks come less than two weeks after Fed Chair Jerome Powell said inflation is still too high and could require more rate increases, though he noted policymakers will “proceed carefully” before moving. More